Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update

Core Viewpoint - Inventiva, a clinical-stage biopharmaceutical company, reported its financial results for Q1 2024, highlighting significant cash usage in operations and R&D, while also providing updates on its clinical trials and corporate governance [1][7]. Financial Results - As of March 31, 2024, the company's cash and cash equivalents were €11.0 million, down from €26.9 million at the end of 2023. Short-term deposits were €0.1 million, and long-term deposits were €19.0 million [2][10]. - Net cash used in operating activities for Q1 2024 was (€29.4) million, an increase from (€20.4) million in Q1 2023. R&D expenses rose by 82% year-over-year, driven by costs related to the NATiV3 Phase III clinical trial [3]. - Net cash used in investing activities was (€10.3) million in Q1 2024, compared to (€8.4) million in Q1 2023, primarily due to changes in deposits [4]. - The company generated €23.7 million in financing activities during Q1 2024, a significant increase from (€1.2) million in Q1 2023, attributed to a €25 million loan from the European Investment Bank [5]. Corporate Update - The company appointed Andre Turenne to its Board of Directors, pending shareholder ratification [9][11]. - The NATiV3 Phase III clinical trial for lanifibranor continues without protocol modifications, with 280 sites in 15 countries resuming patient screening [10][20]. - The anticipated last patient first visit for the NATiV3 trial is targeted for the first half of 2024 [12]. Research and Development - Inventiva's lead product candidate, lanifibranor, is in a pivotal Phase III trial for MASH/NASH, a chronic liver disease with no approved therapies [17]. - The company has suspended clinical efforts for odiparcil to focus on lanifibranor and is reviewing options for its further development [18]. - The company has a robust scientific team and an extensive library of approximately 240,000 pharmacologically relevant molecules [19].